Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice

P. Brusa, F. Pietribiasi, G. Bussolati, F. Dosio, R. Arione, P. M. Comoglio, M. Prat, L. Cattel

Research output: Contribution to journalArticle

Abstract

A blocked immunotoxin, consisting of ricin and AR-3 monoclonal antibody joined by a short thioether bond, was previously synthesized. This conjugate had lost the ability to bind the galactosidic residues of Sepharose 6B, probably because of the steric restraint of the antibody molecule on the ricin B chain. In in vitro assays immunotoxin was active only on cells expressing the corresponding AR-3 epitope. The in vivo activity of our blocked immunotoxin was assessed by injecting it directly into the peritoneal cavity of tumour-bearing nude mice. The animals were i.p. grafted with the HT-29 cell line, which was derived from a human colorectal adenocarcinoma expressing the antigen CAR-3, against which the AR-3 monoclonal antibody is directed. The best protocol tested, to arrive at the optimal regimen for the i.p. blocked immunotoxin therapy, required the administration of the immunotoxin (2 μg) on days 4 and 6 after the graft. The mice were killed on different subsequent days to determine the therapeutic effects. Histological sections of the different organs were prepared and stained with haematoxylin/eosin and were also examined by an immunocytochemical method with AR-3 monoclonal antibody to confirm the presence of the relating antigen on the tumour cell surface. The blocked immunotoxin substantially suppressed tumour growth of the grafted HT-29 cells, without showing any undesirable ricin toxicity. Most importantly, established transplanted HT-29 tumour cells treated with blocked immunotoxin almost completely regressed, while under the same conditions the not blocked immunotoxin, an irrelevant immunotoxin, ricin, and the AR-3 alone failed to inhibit tumour growth.

Original languageEnglish
Pages (from-to)185-192
Number of pages8
JournalCancer Immunology, Immunotherapy
Volume29
Issue number3
DOIs
Publication statusPublished - Jul 1989

Fingerprint

Ricin
Immunotoxins
Nude Mice
Antibodies
Neoplasms
HT29 Cells
Therapeutics
Monoclonal Antibodies
Peritoneal Cavity
Neoplasm Antigens
Therapeutic Uses
Sulfides
Hematoxylin
Eosine Yellowish-(YS)
Growth
Sepharose
Epitopes
Adenocarcinoma
Transplants
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Immunology
  • Cancer Research

Cite this

Blocked and not blocked whole-ricin-antibody immunotoxins : Intraperitoneal therapy of human tumour xenografted in nude mice. / Brusa, P.; Pietribiasi, F.; Bussolati, G.; Dosio, F.; Arione, R.; Comoglio, P. M.; Prat, M.; Cattel, L.

In: Cancer Immunology, Immunotherapy, Vol. 29, No. 3, 07.1989, p. 185-192.

Research output: Contribution to journalArticle

Brusa, P. ; Pietribiasi, F. ; Bussolati, G. ; Dosio, F. ; Arione, R. ; Comoglio, P. M. ; Prat, M. ; Cattel, L. / Blocked and not blocked whole-ricin-antibody immunotoxins : Intraperitoneal therapy of human tumour xenografted in nude mice. In: Cancer Immunology, Immunotherapy. 1989 ; Vol. 29, No. 3. pp. 185-192.
@article{ad97eca705bf4b48ad449be9f8c7042f,
title = "Blocked and not blocked whole-ricin-antibody immunotoxins: Intraperitoneal therapy of human tumour xenografted in nude mice",
abstract = "A blocked immunotoxin, consisting of ricin and AR-3 monoclonal antibody joined by a short thioether bond, was previously synthesized. This conjugate had lost the ability to bind the galactosidic residues of Sepharose 6B, probably because of the steric restraint of the antibody molecule on the ricin B chain. In in vitro assays immunotoxin was active only on cells expressing the corresponding AR-3 epitope. The in vivo activity of our blocked immunotoxin was assessed by injecting it directly into the peritoneal cavity of tumour-bearing nude mice. The animals were i.p. grafted with the HT-29 cell line, which was derived from a human colorectal adenocarcinoma expressing the antigen CAR-3, against which the AR-3 monoclonal antibody is directed. The best protocol tested, to arrive at the optimal regimen for the i.p. blocked immunotoxin therapy, required the administration of the immunotoxin (2 μg) on days 4 and 6 after the graft. The mice were killed on different subsequent days to determine the therapeutic effects. Histological sections of the different organs were prepared and stained with haematoxylin/eosin and were also examined by an immunocytochemical method with AR-3 monoclonal antibody to confirm the presence of the relating antigen on the tumour cell surface. The blocked immunotoxin substantially suppressed tumour growth of the grafted HT-29 cells, without showing any undesirable ricin toxicity. Most importantly, established transplanted HT-29 tumour cells treated with blocked immunotoxin almost completely regressed, while under the same conditions the not blocked immunotoxin, an irrelevant immunotoxin, ricin, and the AR-3 alone failed to inhibit tumour growth.",
author = "P. Brusa and F. Pietribiasi and G. Bussolati and F. Dosio and R. Arione and Comoglio, {P. M.} and M. Prat and L. Cattel",
year = "1989",
month = "7",
doi = "10.1007/BF00199994",
language = "English",
volume = "29",
pages = "185--192",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - Blocked and not blocked whole-ricin-antibody immunotoxins

T2 - Intraperitoneal therapy of human tumour xenografted in nude mice

AU - Brusa, P.

AU - Pietribiasi, F.

AU - Bussolati, G.

AU - Dosio, F.

AU - Arione, R.

AU - Comoglio, P. M.

AU - Prat, M.

AU - Cattel, L.

PY - 1989/7

Y1 - 1989/7

N2 - A blocked immunotoxin, consisting of ricin and AR-3 monoclonal antibody joined by a short thioether bond, was previously synthesized. This conjugate had lost the ability to bind the galactosidic residues of Sepharose 6B, probably because of the steric restraint of the antibody molecule on the ricin B chain. In in vitro assays immunotoxin was active only on cells expressing the corresponding AR-3 epitope. The in vivo activity of our blocked immunotoxin was assessed by injecting it directly into the peritoneal cavity of tumour-bearing nude mice. The animals were i.p. grafted with the HT-29 cell line, which was derived from a human colorectal adenocarcinoma expressing the antigen CAR-3, against which the AR-3 monoclonal antibody is directed. The best protocol tested, to arrive at the optimal regimen for the i.p. blocked immunotoxin therapy, required the administration of the immunotoxin (2 μg) on days 4 and 6 after the graft. The mice were killed on different subsequent days to determine the therapeutic effects. Histological sections of the different organs were prepared and stained with haematoxylin/eosin and were also examined by an immunocytochemical method with AR-3 monoclonal antibody to confirm the presence of the relating antigen on the tumour cell surface. The blocked immunotoxin substantially suppressed tumour growth of the grafted HT-29 cells, without showing any undesirable ricin toxicity. Most importantly, established transplanted HT-29 tumour cells treated with blocked immunotoxin almost completely regressed, while under the same conditions the not blocked immunotoxin, an irrelevant immunotoxin, ricin, and the AR-3 alone failed to inhibit tumour growth.

AB - A blocked immunotoxin, consisting of ricin and AR-3 monoclonal antibody joined by a short thioether bond, was previously synthesized. This conjugate had lost the ability to bind the galactosidic residues of Sepharose 6B, probably because of the steric restraint of the antibody molecule on the ricin B chain. In in vitro assays immunotoxin was active only on cells expressing the corresponding AR-3 epitope. The in vivo activity of our blocked immunotoxin was assessed by injecting it directly into the peritoneal cavity of tumour-bearing nude mice. The animals were i.p. grafted with the HT-29 cell line, which was derived from a human colorectal adenocarcinoma expressing the antigen CAR-3, against which the AR-3 monoclonal antibody is directed. The best protocol tested, to arrive at the optimal regimen for the i.p. blocked immunotoxin therapy, required the administration of the immunotoxin (2 μg) on days 4 and 6 after the graft. The mice were killed on different subsequent days to determine the therapeutic effects. Histological sections of the different organs were prepared and stained with haematoxylin/eosin and were also examined by an immunocytochemical method with AR-3 monoclonal antibody to confirm the presence of the relating antigen on the tumour cell surface. The blocked immunotoxin substantially suppressed tumour growth of the grafted HT-29 cells, without showing any undesirable ricin toxicity. Most importantly, established transplanted HT-29 tumour cells treated with blocked immunotoxin almost completely regressed, while under the same conditions the not blocked immunotoxin, an irrelevant immunotoxin, ricin, and the AR-3 alone failed to inhibit tumour growth.

UR - http://www.scopus.com/inward/record.url?scp=0024349212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024349212&partnerID=8YFLogxK

U2 - 10.1007/BF00199994

DO - 10.1007/BF00199994

M3 - Article

C2 - 2659170

AN - SCOPUS:0024349212

VL - 29

SP - 185

EP - 192

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -